Evidence map›Paper›PMID 9586242›Full record

ReviewTrends in biotechnology1998

Translating old drugs into new treatments: ribosomal frameshifting as a target for antiviral agents.

J D Dinman, M J Ruiz-Echevarria, S W Peltz

Open access · bronzeAbstract readReview
In one paragraph

Review in Trends in biotechnology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Restriction of SARS-CoV-2 replication by targeting programmed -1 ribosomal frameshifting.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Translation Elongation and Recoding in Eukaryotes.Cold Spring Harbor perspectives in biology · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Mimicking Ribosomal Unfolding of RNA Pseudoknot in a Protein Channel.Journal of the American Chemical Society · 2015
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

J D DinmanDepartment of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway 08854, USA.
M J Ruiz-Echevarria
S W Peltz
Johnson University · US

Funding

Translational Fidelity in EukaryotesR01GM058859 · NIGMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI DINMAN, JONATHAN D · 1999 to 2011
$3.8M
NONSENSE-MEDIATED MRNA DECAY PATHWAYR01GM048631 · NIGMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI PELTZ, STUART W · 1993 to 2005
$2.4M
NIGMS NIH HHS GM48631-01NIGMS NIH HHS R01 GM048631NIGMS NIH HHS R01 GM058859
6 · The paper itself

Abstract

Programmed ribosomal frameshifting is used by many viruses to regulate the production of structural and enzymatic proteins. Altering the frameshifting efficiencies disrupts the virus life cycle and eliminates or reduces virus production. Ribosomal frameshifting therefore provides a unique target on which antiviral agents can function. This article describes a series of rapid assay strategies that have been developed and used to identify potential antiviral agents that target programmed -1 ribosomal frameshifting.

Indexed as

Frameshifting, RibosomalAntiviral AgentsVirusesVirus Physiological PhenomenaAntiviral Agents

Identifiers

PMID9586242
PMCPMC7127214
OpenAlexW2107737193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.